Jump to content

Atomoxetine

From Pharmacopedia
Revision as of 10:50, 17 May 2026 by MDElliottMD (talk | contribs) (Recategorize: Stimulants -> Psychostimulants)
NRI, ADHD medicine
Atomoxetine
Strattera

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions4 edges
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
Phenotype:CYP2D6 poor metabolizer dose increase CPIC A 75 / 100
CPIC rec 8093480 [Strong]: Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose. CPIC pair-level A (CYP2D6 and Atomoxetine) [PMID 30801677]
Phenotype:CYP2D6 ultrarapid metabolizer dose increase CPIC A 50 / 100
CPIC rec 8093460 [Moderate]: Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. CPIC pair-level A (CYP2D6 and Atomoxetine) [PMID 30801677]
Phenotype:CYP2D6 normal metabolizer dose increase CPIC A 50 / 100
CPIC rec 8093471 [Moderate]: Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. CPIC pair-level A (CYP2D6 and Atomoxetine) [PMID 30801677]
Phenotype:CYP2D6 intermediate metabolizer dose increase CPIC A 50 / 100
CPIC rec 8093476 [Moderate]: Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. CPIC pair-level A (CYP2D6 and Atomoxetine) [PMID 30801677]

Patient experience

No patient-experience reports yet.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Pharmacy
Common uses
Classification(s)
Classes
NRI, ADHD medicine
Pharmacology
Purported mechanism
Selective norepinephrine reuptake inhibitor
Pharmacopedia is intended for reference. Nothing here is advice. In an emergency call 911; US Poison Control 1-800-222-1222. See the full disclaimer.